Reaction

Joint Arthroplasty reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,771 reports · 47 co-occurring drugs

As of the last recalculation, Joint Arthroplasty appears in 1,771 FAERS reports alongside 47 co-occurring drug terms. The strongest observed disproportionality signal is ANAKINRA (PRR 71.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Anakinra	95	71.1	71.5
Canakinumab	60	67.4	67.8
Minocycline	34	34.9	35.0
Tocilizumab	234	27.6	27.7
Hydroxychloroquine	158	27.2	27.3
Leflunomide	208	26.3	26.4
Sulfasalazine	141	22.9	23.0
Hydroxychloroquine Sulfate	145	20.3	20.3
Abatacept	197	18.7	18.7
Pseudoephedrine Hydrochloride	16	18.5	18.5
Tofacitinib Citrate	20	18.1	18.1
Upadacitinib	114	17.5	17.5
Pseudoephedrine Hcl	16	17.2	17.2
Alendronate Sodium	132	16.5	16.6
Cortisone Acetate	17	16.3	16.4
Desoximetasone	25	15.6	15.6
Diclofenac Potassium, Film Coated	10	14.0	14.1
Diclofenac Potassium Tablets	10	14.0	14.0
Etanercept	516	13.9	13.9
Tofacitinib	193	13.7	13.7
Infliximab	221	13.4	13.5
Methotrexate	358	12.3	12.3
Methotrexate Sodium	395	12.0	12.0
Calcium Gluconate	12	11.8	11.8
Diclofenac Potassium	10	10.9	10.9
Rituximab	154	9.3	9.3
Golimumab	65	9.2	9.2
Sarilumab	19	8.5	8.5
Adalimumab	405	8.4	8.4
Naproxen Sodium Tablet, Coated	9	7.8	7.9
Naproxen Sodium, Coated Tablets	9	7.8	7.9
Cetirizine Hydrochloride Allergy	20	7.8	7.8
Cetirizine Hydrochloride Tablets	20	7.8	7.8
Naproxen Sodium 220Mg	9	7.8	7.8
Diclofenac Sodium 1%	22	7.3	7.3
Diclofenac Sodium Topical	22	7.3	7.3
Diclofenac Sodium Topical Gel, 1%	22	7.3	7.3
Certolizumab Pegol	64	6.6	6.6
Emtricitabine And Tenofovir Alafenamide	6	6.2	6.2
Risankizumab-Rzaa	36	5.3	5.3
Teriparatide	43	4.6	4.6
Loratadine And Pseudoephedrine Sulfate	3	4.4	4.4
Romosozumab-Aqqg	5	4.3	4.3
Ustekinumab	32	3.7	3.7
Emtricitabine And Tenofovir Disoproxil Fumarate	14	3.6	3.6
Emicizumab	3	2.9	2.9
Apremilast	27	2.2	2.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.